Numerous studies investigated the associations of VDR polymorphisms with various types of cancer, suggesting an influence on cancer risk. FokI is one of the most frequently analysed polymorphisms but the results from single studies are contradictory. we performed a meta-analysis looking at the association between the FokI and all cancer sites and investigating sources of heterogeneity. we identified 77 independent studies up to April 2014. we presented the summary odds ratios (SORs) by cancer sites, ethnicity and study features. we found a significant association between FokI and ovarian cancer for ff genotype versus FF with no heterogeneity: SOR = 1.20 (95% Ci: 1.02-1.41, I 2 = 0%). Moreover, we found a significant increased risk of any cancer: SOR = 1.08 (95% Ci: 1.01-1.16, I 2 = 58%). A significant increased risk of any cancer is confirmed among Caucasian, among studies in Hardy-weinberg equilibrium and nested case-control studies. Furthermore, among studies in Hardy-weinberg equilibrium, skin cancer was found significantly associated with FokI: SOR = 1.24 (95% Ci: 1.01-1.54; I 2 = 24%) for ff versus FF. The estimated number of cases attributable to ff genotype is 4221 for ovarian cancer and 52 858 for skin cancer worldwide each year. No indication for publication bias was found for any cancer site. in conclusion, we found an overall significant association of FokI polymorphism with any cancer, with differential effect by ethnicity. in particular, the summary estimates indicate an increase risk for ovarian and skin cancer for ff versus FF. However, other factors may act modifying the association, and further studies are needed to clarify the impact on cancer risk.
introduction
Cancer is the leading cause of death worldwide (1) , as a result of population ageing and a complex interaction between an individual's genetic makeup and exposure to environmental risk factors. Biological and epidemiologic data suggest that vitamin D status could affect cancer risk and play a role in cancer prevention (2, 3) . Vitamin D is involved in mineral metabolism and bone growth and influences the intestinal absorption of calcium and uptake of phosphate and magnesium. Vitamin D from diet and sunlight sources is hydroxylated in the liver to 25-hydroxyvitamin D that is then further hydroxylated to 1,25-dihydroxyvitamin D in the kidney and other tissues. 1,25-dihydroxyvitamin D is the biologically active metabolite that binds to vitamin D receptors (VDR). VDR is an intracellular nuclear receptor active in over 30 different human tissues, its activation involves over 60 genes in different cell lines (2) . VDR belongs to the superfamily of nuclear receptors for steroid hormones and regulates gene expression by acting as a ligand activated transcription factor. It is active in different human tissues and organs, such as skin, brain, reproductive organs and certain cells of the immune system. Numerous are the identified polymorphisms of the VDR gene, and they may influence receptor affinity, binding to nuclear DNA, RNA transcription, and protein synthesis (4, 5) . The presence of an f allele at FokI leads to the production of a longer protein (three amino acids more) than that produced by the F allele. The f allele exerts less transcriptional activity than the shorter protein as reported by several studies (4, 6) and it is consequently associated with lower VDR activity. In addition, it is well-established that VDR genotypes vary widely by ethnicity (5) and the f allele of FokI occurs less frequently in Africans when compared with Caucasians and Asians. Associations of VDR polymorphisms with various types of cancer have been widely investigated. Our group performed two meta-analysis (7, 8) , suggesting significant associations for breast, skin, prostate cancers and, in general, for Caucasians. However, between-study heterogeneity was considerable and many new studies on vitamin D and cancer were published in the last years, including cancer sites that were not analysed previously. Thus, we updated our meta-analyses on FokI polymorphism of VDR gene and all cancer sites, investigating possible sources of heterogeneity.
Material and methods
A systematic literature search and quantitative analysis were planned, conducted and reported following Meta-analysis Of Observational Studies in Epidemiology guidelines (9) .
Literature search and data extraction
Published reports were obtained from the following databases using validated search strategies: PUBMED, Ovid Medline, EMBASE, ISI Web of Knowledge up to April 2014, with no language, time or geographical restriction. The search was carried out to assess the association between the FokI polymorphism of VDR gene and risk of different types of cancer. We used the MeSH index terms: 'VDR', 'Vitamin D receptor', or 'FokI' in combination with 'cancer' or 'tumour'. We also performed manual searches of references cited in the retrieved articles and preceding reviews on the topic. Ecological studies, case reports, reviews and editorials were not considered eligible. We screened titles and looked at abstracts when the title suggested a study possibly meeting our inclusion criteria. If the abstract content was relevant, full copies of articles were retrieved and fully read by at least two co-authors.
Two of the authors (S.R. and E.P.) independently selected the articles. We selected:
1. Studies reporting sufficient information to estimate the relative risk and 95% confidence intervals (CIs) for the association between FokI polymorphism and cancer [odds ratios (OR), relative risks or crude data and corresponding standard errors, variance, confidence intervals or P-value of the significance of the estimates]. 2. Studies which are independent and did not present duplicate results published in another article. When several articles concerned the same subjects, results from the publication using the largest sample size were used.
We included studies only with disease-free controls: e.g. studies with benign prostatic hyperplasia (10) or basal-cell papilloma (11) taken as controls were excluded.
A standardized data-collection protocol was used for gathering the relevant data from each selected article. When data were reported by ethnicity or by cancer site, the estimates were extracted separately for the different factors. Data extraction was done by one co-author (E.P.) in a pre-defined database, and after checked by another co-author (S.R.). For each study selected for this meta-analysis we pulled out information on authors, journal and year of publication, country, ethnicity of study population, source of controls (hospital or population), number of cases and controls (separately for FF, Ff and ff genotypes), OR estimates and the corresponding CI along with variables adjusted for in the analysis.
In our analysis we considered as wild-type the homozygous genotype FF because F is the more prevalent allele. When it was possible, we considered fully adjusted estimates of the association between VDR polymorphism and cancer for both Ff and ff carriers compared with wild-type subjects.
Statistical analysis
The summary odd ratios (SORs) for Ff and ff carriers compared with FF subjects were calculated. Every OR and corresponding CIs were transformed into Abbreviations: CC, case-control study; CI, confidence interval; HW, HardyWeinberg; NCC, nested case-control study; OR, odds ratio; SOR, summary odds ratio; VDR, vitamin D receptor.
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log OR, and the corresponding variance was calculated using the formula proposed by Greenland (12) . When no estimates were given, crude estimates were calculated from tabular data. We used Woolf's formula to evaluate the standard error of the log OR. The SOR was estimated by pooling the study-specific estimates with the random effects models as described by van Houwelingen et al. (13) , i.e. with summary effect size obtained from maximum likelihood estimation. CIs were computed assuming an underlying t-distribution.
The measure of heterogeneity I 2 has been considered to compare between heterogeneities for different numbers of pooled studies. It can be interpreted as the percentage of total variation across several studies that is attributable to heterogeneity: larger values of I 2 indicate high heterogeneity (12) . A threshold of I 2 <50% is generally considered an acceptable level of variability (14) . We presented SORs separately for each cancer site and also stratified for ethnicity (Caucasian and ethnic groups other than Caucasian); moreover, we produced forest plots for each cancer site (for which were found at least three papers) (Supplementary Figures 1-7 , available at Carcinogenesis Online).
Deviations from the Hardy-Weinberg (HW) in controls were assessed for each study using chi-square test.
To assess the influence of possible sources of bias, we considered the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist proposed for observational epidemiologic studies (15) . According to the STROBE checklist, using meta-regression, we evaluated between-study heterogeneity assessing the influence of different study features, such as the accurate description of the study population and study design, appropriate statistical methods, and adequate and correct reporting of results. We also examined changes in results after exclusion of specific studies to evaluate the stability of the pooled estimates. Meta-regressions and subgroup analyses were carried out to quantify between-study heterogeneity. Heterogeneity was investigated by looking at all the possible factors that could influence the estimates (study design, type of controls, adjustment for confounding factors, deviation from HW equilibrium, latitude and features of the population such as ethnicity). We also evaluated if allele frequency was associated with latitude and ethnicity, with a GLM model, weighting for the study size. Publication bias was evaluated graphically with a funnel plot; and we conducted the Macaskill test (16) that is more powerful than the Egger's test when <20 estimates are included in the analysis.
To translate the estimation of risk in the current study to the burden in the general population, we calculate the number of cases attributable to FokI mutation, extracting cancer incidence data from GLOBOCAN (17) . The attributable fraction was estimated with Levin's formula using the proportion of subjects with ff genotypes among controls (a weighted average of proportions of singles studies) and the summary ORs of our meta-analysis.
All the statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC; version 9.2).
Results
We identified 77 eligible studies to investigate the associations of FokI polymorphism with cancer risk. Selected studies presented data for several cancer sites: prostate, breast, colorectal, skin, renal cell cancer, ovary, bladder, brain, male breast, esophageal adenocarcinoma, hepatocellular carcinoma, head and neck, nasopharyngeal carcinoma, oral squamous cell carcinoma, thyroid carcinoma, myeloma, non-Hodgkin's lymphoma, pancreas and sarcoma. The main characteristics of the reviewed studies are presented in Table I . A total of 42 408 cases and 52 246 controls were included. Most of the studies were carried out in USA and Caucasian population (Table I) . For 10 studies, a significant departure from HW equilibrium was observed (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . On average, the prevalence of the f allele was 37% (from 18% to 63%) among control subjects (Table I) .
In Table II (Table II) . Stratifying by ethnicity, we found differential associations with cancer risk comparing Caucasians versus other ethnic groups (Table  III) . Among Caucasians, the summary risk estimates suggested a significant borderline increased risk of any cancer: SORs are 1.07 (95% CI: 1.00-1.15; I 2 = 55%) and 1.04 (95% CI: 1.00-1.09; I 2 = 40%) for the ff and Ff genotype versus FF, respectively (Table III) Excluding studies in HW disequilibrium or considering the best study designs (nested case-control studies), results are confirmed (data not shown). In particular, we estimate a significant increased risk of any cancer for both comparisons of genotypes: SOR = 1.07 (95% CI: 1.01-1.14) and SOR = 1.15 (95% CI: 1.05-1.25) for ff and fF versus FF, respectively. Similar results are obtained when we considered only Caucasians: SOR = 1.07 (95% CI: 1.00-1.15) and SOR = 1.14 (95% CI: 1.03-1.25) for ff and fF versus FF, respectively. Furthermore, among studies in HW equilibrium, skin cancer was found significantly associated with FokI: SOR = 1.24 (95% CI: 1.01-1.54) for ff versus FF, with not high heterogeneity: I 2 = 24%. Looking at study design, we found that prospective nested casecontrol studies confirm an increased risk for any cancer among Caucasians: SOR = 1.07 (95% CI: 1.00-1.15) for ff versus FF.
Furthermore, we found that the f allele frequency was significantly different by ethnicity (P < 0.0001) with lower values among AfricanAmerican than other groups and there is a significant (P = 0.04) increasing trend of f allele frequency by latitude.
No indication for publication bias was found for any cancer site. Proportion attributable fractions are 1.8 and 2.1 for ovarian and skin cancer, respectively. Considering data from GLOBOCAN (17) and from the World Health Organization (95) we obtain that 4221 ovarian cancer and 52 858 skin cancer worldwide, each year, can be attributable to ff genotype.
Discussion
In the present meta-analysis, we examined the FokI VDR polymorphism for its association with cancer risk. Pooling together a total of 77 studies, we provide evidence that ff genotypes when compared with FF was associated with a 20% significant increase risks in ovarian cancer, with no heterogeneity, and with a 8% in all cancers combined (I 2 = 58%). The overall increased risk is confirmed among Caucasian, among studies in HW equilibrium and among prospective nested case-control studies. Furthermore, among studies in HW equilibrium, we provide evidence that ff genotypes was associated with a 24% significant increase risks in skin cancer, with no big heterogeneity (I 2 = 24%). The effect of the f allele on ovarian cancer risk observed in our meta-analysis seems to reflect an underlying biological phenomenon related to disease development. Women carrying the f allele have a less active VDR, which may increase the ovarian cancer risk. Two previous pooled analysis (75, 76) , carried on Caucasians, found an analogous significant increase risk, but the association was stronger among younger and premenopausal women (76) . The most recent meta-analysis that has been published on FokI and ovarian cancer (96) presented similar risk estimates.
In our study, the f allele was at significant high risk for cancer especially in Caucasians, and this result is confirmed among studies in HW equilibrium and among prospective nested case-control studies. The estimates regarding Caucasians in the most recent meta-analysis (97) did not reach significance. However, in general, the main reason for differences with previous meta-analyses (97, 98 ) is due to different studies included. In fact, we tried to be very careful in identifying independent studies and including only studies with healthy controls.
We found that the f allele occurs with an intermediate frequency in Caucasian compared with Africans and Asians, with the higher frequency reported in Asians population, as reported by other authors (5): Caucasians 39%, Africans 24% and Asians 46. The hypothesis that the f allele would be less functional effective than F allele is known and it may explain the consequent decreased anticancer effect, but this does not explain differences by races. Ethnicity seems to be an important biological factor which may influence the VDR functions, but is difficult to fully understand the consequence and the potential clinical implications. There may be ethnic differences in the dietary habits, sun exposure together with other genetic factors, which might interfere with FokI polymorphisms. For example, the opposite direction of the risk estimates for prostate cancer by ethnicity can be noticed: in Caucasians we have an increased risk and in non-Caucasians a reduced risk (Table III) . On the other hand, the authors of a big study (the Physicians' Health Study) (36) found an increased risk associated with the less functional FokI ff genotype only in the presence of low 25-hydroxyvitamin D status, whereas John et al. (99) found that FokI ff genotype was associated with a significant increased prostate cancer risk in the presence of high sun exposure: OR = 2.2 (95% CI: 1. Two recent reviews on skin cancer (100,101) support the hypothesis that the f allele can interact with other factors such as skin color (P = 0.03) and moles (P = 0.02). For skin cancer we found similar results to our previous meta-analyses (7, 8) , even if only in studies with HW equilibrium (SOR = 1.24; 95% CI: 1.01-1.54 for ff versus FF). The most recent meta-analysis (98) on skin cancer found a significant increased risk also for melanoma and non-melanoma skin cancer separately. Our meta-analysis includes one more recent article (73) and excludes one study because of not healthy controls (11) .
Vitamin D receptor polymorphism FokI and cancer risk
The biggest study on breast cancer (50) was a pooled analysis of six cohorts carried on in USA and Europe. They found a modest significantly increase in breast cancer risk associated with the ff genotype (OR = 1.16; 95% CI: 1.04-1.28), including mainly Caucasian women, except for one study. However, the highest significantly increased risk of breast cancer with FokI was reported by Barroso et al. (47) in a small study performed in Spain (OR = 1.65; 95% CI: 1.02-2.65) characterized by the population phenotype of southern Europe. Only one study, Anderson et al. (19) found a significant inverse association of FokI ff genotype with breast cancer risk (OR = 0.71; 95% CI: 0.57-0.88). It is unclear the reason for this association, but the study had a big sample size and the estimates were adjusted for age. However, it is worth to note that a significant departure from HW equilibrium was observed in this study.
We also found recent studies showing a significant association for ff when compared with FF for follicular thyroid (84), brain (25) , myeloma (90) and pancreatic cancer (94) with a significant at 3-to 5-fold increased risk. One study (88) showing a significant 36% inverse association for head and neck cancer. Two more studies observed a significant inverse association with bladder (24) and brain cancer risks (82) comparing Ff with FF genotype.
Through a meta-analytic approach, we were able to provide powerful summary risk estimates for the four most studied cancer types. We were able to provide a complete picture of the role of VDR FokI polymorphism on cancer risk considering ethnicity. Some limitations should also be noted. The number of studies for some cancer sites included in the meta-analysis was too few to be conclusive. Secondly, we extracted fully adjusted estimates, for known confounding factors; however, in some studies we had to calculate unadjusted risk estimates using crude data available in the text. It is possible that the observed relationships could be partly due to unmeasured or residual confounding that could modify the estimates.
In conclusion, our study represents an updated and comprehensive meta-analysis on the role of the FokI polymorphism on cancer risk. Including 77 eligible studies and 42 408 cases, we provided evidence that carrying the FokI ff genotype significantly increased ovarian cancer risk by 20% and cancer risk at any site by 8%. Among Caucasians the summary risk estimates suggested a significant borderline increased risk of any cancer for the ff and Ff genotype versus FF. Excluding studies in HW disequilibrium, we provide evidence that ff genotypes was associated with a 24% significant increase risks in skin cancer. Further studies are needed to pin down the role of the VDR metabolism, including 25-hydroxyvitamin D level, its binding protein (GC) polymorphisms, ethnicity and cancer risk. Supplementary Figures 1-7 Bold text indicates significant estimates.
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